An Update on IBD Pivotal Clinical Trials from the United European Gastroenterology Week (UEGW) 2020 & the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
Cornerstones is pleased to invite you to view our online webinar that presents a top-line summary of the key IBD pivotal trials from the UEGW and ACG virtual conferences. This program was developed by an international group of IBD experts who reviewed all IBD-related clinical trials presented at UEGW and ACG and collaborated with study authors to compile a condensed update on the best research and most clinically pertinent data. As a unique feature, the webinar includes presentations from several primary authors of key clinical trials. This in-depth update provides you with valuable education to implement new understanding into your ulcerative colitis and Crohn’s disease practice.
Overview of IBD Therapeutic Targets & Pipeline
Top Line Trial Results: SERENE-UC, ENVISION 1, VISIBLE 1, HIBISCUS, HICKORY, GARDENIA, LAUREL, STARDUST, UNIFI, GALAXI 1, SERENITY, RIVETING, OCTAVE, CELEST, SELECTION, TRUE NORTH, TOUCHSTONE, OASIS
Course Directors & Presenters
Professor of Pediatrics and Medicine, Icahn School of Medicine
Chief, Pediatric Gastroenterology and Nutrition, Mount Sinai Kravis Children’s Hospital
Co-Director, IBD Preconception and Pregnancy Planning Clinic, Mount Sinai School of Medicine
The Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
The University of Chicago Medicine
Assistant Professor of Medicine; The University of Chicago Medicine Chicago, IL
Assistant Professor Pediatrics; Icahn School of Medicine at Mount Sinai Mount Sinai Kravis Children’s Hospital New York, NY
Clinical Trial Presenters
Humanitas Research Hospital; Milan, Italy
Tel Aviv University; Tel Aviv, Israel
University of California San Diego School of Medicine; La Jolla, CA
Séverine Vermeire, MD, PhD
University Hospitals Leuven; Leuven, Belgium
Course Development Faculty
Professor of Inflammatory Bowel Disease, Consultant Gastroenterologist, Barts Health NHS Trust
Professor of Inflammatory Bowel Disease, Queen Mary University of London
Peter Irving, MA, MD, FRCP
Consultant Gastroenterologist, Guy’s and St. Thomas’ NHS Foundation Trust
Honorary Reader, King’s College London
Support for this activity has been made possible through educational grants from:
Bristol Myers Squibb
Janssen Biotech, Inc. (administered by Janssen Scientific Affairs, LLC)
Takeda Pharmaceutical USA
Release Date: December 14, 2020
Expiration Date: December 14, 2021
After successful completion of this CME/CE activity, participating members of the IBD care team are expected to be better able to:
Incorporate advances in therapeutic options and understanding of biologics, small molecules, biosimilars, and non-medical therapies for the treatment of Crohn’s disease & ulcerative colitis.
Consider the implications for short-term outcomes in IBD based on clinical presentation and treatment strategy.
Collaborate with other members of the care team to individualize management for people living with IBD.
The Best of UEGW & ACG 2020 program is specifically designed for gastroenterologists, nurse practitioners, physician assistants, and fellows involved in the management of patients with inflammatory bowel disease.
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Cornerstones Health. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of CME, Inc., designates this educational activity for 1.5 ANCC contact hours (1.0 pharmacotherapeutic contact hours). California: Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.5 contact hours.
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Please see slides at the beginning of the activity for faculty and planner disclosure information.